Back to Search Start Over

Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation

Authors :
Wang, Changshan
Oshima, Motohiko
Sato, Daisuke
Matsui, Hirotaka
Kubota, Sho
Aoyama, Kazumasa
Nakajima-Takagi, Yaeko
Koide, Shuhei
Matsubayashi, Jun
Mochizuki-Kashio, Makiko
Nakano-Yokomizo, Takako
Bai, Jie
Nagao, Toshitaka
Kanai, Akinori
Iwama, Atsushi
Sashida, Goro
Source :
Journal of Clinical Investigation. September, 2018, Vol. 128 Issue 9, p3872, 15 p.
Publication Year :
2018

Abstract

Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is a new pathological entity with poor outcomes in T cell ALL (T-ALL) that is characterized by a high incidence of loss-of-function mutations in polycomb repressive complex 2 (PRC2) genes. We generated a mouse model of ETP-ALL by deleting Ezh2, one of the PRC2 genes, in p53-null hematopoietic cells. The loss of Ezh2 in p53-null hematopoietic cells impeded the differentiation of ETPs and eventually induced ETP-ALL-like disease in mice, indicating that PRC2 functions as a bona fide tumor suppressor in ETPs. A large portion of PRC2 target genes acquired DNA hypermethylation of their promoters following reductions in H3K27me3 levels upon the loss of Ezh2, which included pivotal T cell differentiation-regulating genes. The reactivation of a set of regulators by a DNA-demethylating agent, but not the transduction of single regulator genes, effectively induced the differentiation of ETP-ALL cells. Thus, PRC2 protects key T cell developmental regulators from DNA hypermethylation in order to keep them primed for activation upon subsequent differentiation phases, while its insufficiency predisposes ETPs to leukemic transformation. These results revealed a previously unrecognized epigenetic switch in response to PRC2 dysfunction and provide the basis for specific rational epigenetic therapy for ETP-ALL with PRC2 insufficiency.<br />Introduction Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as a new pathological entity of T cell ALL (T-ALL) that shows resistance to conventional chemotherapies and has [...]

Details

Language :
English
ISSN :
00219738
Volume :
128
Issue :
9
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.553759912
Full Text :
https://doi.org/10.1172/JCI94645